Ford Equity US Rating and Forecast Report
Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.Sorrento Therapeutics is a clinical stage biotechnology company focused on delivering clinically therapies to patients and their families, globally. The company primarily focus on therapeutics areas in Immune-Oncology and Non-Opioid Pain Management. The company also has programs assessing the use of its technologies and products in autoimmune, inflammatory and neurodegenerative diseases. The company's Clinical Programs includes: CD38 Directed chimeric antigen receptor T-cell therapy (CAR-T) Program, which is for the treatment of multiple myeloma and for additional potential indications; and Carcinoembryonic antigen Directed CAR-T Program, which is for the regional treatment of liver metastases.
Ford US Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.